AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purification

The industry is moving from ex vivo to in vivo gene delivery, a change that forces viral vector manufacturers to rethink scale, purity, cell lines and analytical methods. In in vivo approaches the vector itself becomes the drug, requiring tighter control and larger production volumes.

AGC Biologics is responding by developing stable producer cell lines and investing in next‑gen purification technologies. The company also plans deeper characterization of vectors to meet the stricter quality demands of in vivo therapies.

These shifts could reshape the manufacturing landscape for lentiviral and AAV platforms, making production more scalable and potentially lowering costs for future gene‑therapy products.